Agency for Medicinal Products and Medical Devices of the Republic of Slovenia
JAZMP is ambitious to further actively participate in assessment of marketing authorisation applications. In order to strengthen Slovenia’s position in the regulatory EU environment, one of the strategic objectives of […]
JAZMP acting as Reference Member State (RMS) in MRP and DCP procedures Read More »
The joint HMA-EMA Network Data Steering Group (NDSG) is running an EU survey to inform research priorities for AI use in the development and evaluation of medicines. To access the
AI research priorities survey Read More »
The Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA) will host a multi-stakeholder workshop on artificial intelligence (AI) on 20 and 21 November 2025. The workshop has
HMA / EMA multi-stakeholder workshop on artificial intelligence in medicines Read More »
The Accelerating Clinical Trials (ACT EU) initiative aims to identify gaps, issues and bottlenecks (regulatory, resourcing, operational) that prevent non-commercial sponsors from setting up and conducting clinical trials and multinational
EU strengthens support for non-commercial sponsors of clinical trials Read More »
The Accelerating Clinical Trials in the EU (ACT EU) initiative will hold its annual Multi-Stakeholder Platform meeting on 29 October 2025. The event, organised by EMA, will gather regulators, academia,
Upcoming ACT EU Multi-Stakeholder Platform Annual Meeting Read More »
As part of the Joint Action “Supporting the increased capacity and competence building of the EU medicines regulatory network” (IncreaseNET), funded under the EU4Health programme 2021–2027, the Italian Medicines Agency
call for expressions of interest Read More »
Agency for Medicinal Products and Medical Devices of the Republic of Slovenia (JAZMP), as the leader of Work Package 4 Sustainability within the EU4Health joint action Reinforced Market Surveillance of
Sustainability workshop of JAMS 2.0 outcomes Read More »
